{"entity":{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","aka":[],"tldr":"A phase 3 trial testing HS-20089 in ovarian cancer, now recruiting.","summary":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06855069, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Multi-centre, Randomised, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Planned enrolment is 468 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-03-07. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06855069","url":"https://clinicaltrials.gov/study/NCT06855069"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["hs-20089"],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06855069","phase":"3","setting":"A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","sponsor":"Hansoh BioMedical R&D","participation":[{"nct":"NCT06855069","source":"https://clinicaltrials.gov/study/NCT06855069","fetchedAt":"2026-10-07T16:55:09.829Z","studySha256":"e1ce7306ad05a82b0cfa21a1d3c16e36d7d0a7505e2ba1bf8484cf2e9c397104","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-17","leadSponsor":"Hansoh BioMedical R&D Company","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":468,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-03-13","startedType":"actual","enrolled":468,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06855069/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}]}}